Certolizumab pegol for the treatment of psoriasis

被引：20

作者：

Campanati, A. ^{[1
]}

Benfaremo, D. ^{[2
]}

Luchetti, M. M. ^{[2
]}

Ganzetti, G. ^{[1
]}

Gabrielli, A. ^{[2
]}

Offidani, A. ^{[1
]}

机构：

[1] Polytechn Marche Univ, Dept Clin & Mol Sci, Dermatol Clin, Ancona, Italy

[2] Polytechn Marche Univ, Internal Med, Dept Clin & Mol Sci, Via Conca 70, I-60020 Ancona, Italy

来源：

EXPERT OPINION ON BIOLOGICAL THERAPY | 2017年 / 17卷 / 03期

关键词：

Certolizumab pegol; psoriasis; psoriatic arthritis; TNF alpha inhibitor; DOUBLE-BLIND; PHASE-III; CLINICAL-RESPONSE; BIOLOGIC THERAPY; CONTROLLED-TRIAL; ALPHA THERAPY; ARTHRITIS; MODERATE; IMMUNOGENICITY; MAINTENANCE;

D O I：

10.1080/14712598.2017.1283401

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Introduction: Psoriasis is a chronic immunomediated and inflammatory disease involving mainly skin and joints, often associated with several metabolic and non-metabolic comorbidities. TNF-alpha inhibitors have shown long-term efficacy and safety/tolerability in psoriasis, and preliminary data support the use of certolizumab pegol (CZP) as well.Areas covered: The authors review the pharmacological properties of CZP, as well as its safety data and efficacy profile. They also review the quality of life outcomes related to CZP in psoriasis. The authors also provide their expert opinion on the subject.Expert opinion: CZP is a promising treatment for psoriasis owing to its rapid reduction of disease activity, long-term therapeutic efficacy - both in bio-naive and non-bio-naive patients, long term safety and low rate of site injection reactions. CZP seems to be a promising therapeutic option for psoriasis patients, although further evidence supporting the continuing clinical program for development of CZP in psoriasis is needed.

引用

页码：387 / 394

页数：8

共 35 条

[1]

[Anonymous], 2016, CIMZ CERT PEG PRESCR

[2]

[Anonymous], 2016, CIMZ CERT PEG SUMM P

[3]

[Anonymous], 2016, CIMZ CERT PEG PRESCR

[4] Induction or Exacerbation of Psoriasis in Patients with Crohn's Disease under Treatment with Anti-TNF Antibodies [J].

Barthel, Christiane ;

Biedermann, Luc ;

Frei, Pascal ;

Vavricka, Stephan R. ;

Kuendig, Thomas ;

Fried, Michael ;

Rogler, Gerhard ;

Scharl, Michael .

DIGESTION, 2014, 89 (03) :209-215

[5] Novel approaches to biological therapy for psoriatic arthritis [J].

Boyd, Tristan ;

Kavanaugh, Arthur .

EXPERT OPINION ON BIOLOGICAL THERAPY, 2016, 16 (02) :173-186

[6] CTACK/CCL27 expression in psoriatic skin and its modification after administration of etanercept [J].

Campanati, A. ;

Goteri, G. ;

Simonetti, O. ;

Ganzetti, G. ;

Giuliodori, K. ;

Stramazzotti, D. ;

Morichetti, D. ;

Bernardini, M. L. ;

Mannello, B. ;

Fabris, G. ;

Offidani, A. .

BRITISH JOURNAL OF DERMATOLOGY, 2007, 157 (06) :1155-1160

[7] ADALIMUMAB MODULATES ANGIOGENESIS IN PSORIATIC SKIN [J].

Campanati, A. ;

Moroncini, G. ;

Ganzetti, G. ;

Pozniak, K. N. ;

Goteri, G. ;

Giuliano, A. ;

Martina, E. ;

Liberati, G. ;

Ricotti, F. ;

Gabrielli, A. ;

Offidani, A. .

EUROPEAN JOURNAL OF INFLAMMATION, 2013, 11 (02) :489-498

[8] Insulin resistance, serum insulin and HOMA-R [J].

Campanati, A. ;

Ganzetti, G. ;

Di Sario, A. ;

Benedetti, A. ;

Offidani, A. .

JOURNAL OF GASTROENTEROLOGY, 2013, 48 (05) :673-673

[9]

Campanati A, 2016, J DERMATOL TREAT, V23, P1

[10] Biologic Therapy in Psoriasis: Safety Profile [J].

Campanati, Anna ;

Ganzetti, Giulia ;

Giuliodori, K. ;

Molinelli, Elisa ;

Offidani, A. .

CURRENT DRUG SAFETY, 2016, 11 (01) :4-11

← 1 2 3 4 →